Eligible investors only · capital at riskThis public page is information for Relevant Persons—not an offer, recommendation or prospectus.Read the legal notice ↓
( 01 )Company + investment
Built to scale
One data core.
Many routes to market.
We have built a machine that systematically reads private healthcare websites across the UK, extracts the treatments and prices they publish, and organises them into one comparable data core. Scattered provider pages become structured supply that consumers can search, compare and act on.
Pre-revenue and raising a further £250,000 at a £3.8m pre-money valuation. Backed by the Google Startup Programme, Innovate UK support and a medical investment syndicate.
Supported byGoogle for StartupsInnovate UKMedical investment syndicate
( 02 )Our viewpoint
The connection problem
Patients struggle to compare. Providers struggle to be discovered.
The shortest path to care starts with connected data. Medeagle builds the intelligence layer that brings both sides together.
Understand intent
Capture the language, questions and signals that reveal what patients are really trying to find.
Structure providers
Make treatment, location, pricing and availability data consistent, connected and reusable.
Move people forward
Connect search phrases, comparison behaviour and enquiry endpoints—tracking and measuring each step while researching NHS patient abandonment and wider demand signals.
( 03 )What Medeagle does
One connected technology layer
From search signal
to provider growth.
A shared data foundation that can power consumer marketplaces, provider products, commercial intelligence, partner fulfilment and—where the evidence supports it—selective ownership.
01 Core practice
Understand what patients need
Demand intelligence
Turn search behaviour, questions and treatment intent into a live picture of medical consumer demand.↗
02 In motion
Structure the supply of care
Provider data graph
Connect treatments, providers, locations, pricing and availability in one reusable intelligence layer.↗
03 Live pathway
Create the connection
Marketplace conversion
Power search, comparison, booking and partner routing that move people towards the right provider.↗
The ultimate medical retailing operating systemFive systems.
Five systems.
One compounding advantage.
The moat is not a static directory. Each layer enriches the next: supply makes comparison possible, demand reveals value, and real commercial outcomes improve the intelligence over time.
Supply graph
Providers, treatments, prices, locations and departments become connected records rather than isolated web pages.
Demand graph
Patient searches, symptoms, questions and intent stages reveal what people need and how close they are to acting.
Page-level advanced SEO structure
Every treatment and provider page becomes a reusable commercial data object that can be compared, ranked and distributed.
Commercial scoring + prospecting
Search volume, competition, provider density, pricing and cost-per-click show which treatments and providers to prioritise for outreach.
Connected enquiry operations
External CRM and workflow systems can distribute, monitor and re-route enquiries; every provider response, question and outcome improves the next match.
● One data foundation. Multiple ways to connect patients and providers.
01SearchCapture patient intent→02CompareMatch structured supply→03BookLearn from conversion
PathwaysSame-day GPOnline GPADHD diagnosisSexual-health home testing
Value moves both ways.
Clearer routes to care.
Comparable treatments, more visible pricing and easier access to suitable providers.
Demand they can act on.
Relevant patient enquiries, stronger visibility and insight into what people need.
Scroll to understand
( 05 )Launch tour + partner offer
See the marketplace in motion
From patient need
to provider opportunity.
A practical tour of FastTrack Treatment—how patients discover and compare treatment, how providers connect with active demand, and how Medeagle structures the intelligence underneath.
FastTrack TreatmentFilm / 01
( 06 )The investment case
Why nowIndependent market signals
The timing
The market is moving before it can be compared.
Three forces are converging: NHS pressure creates direct-pay demand, consumers expect to compare care, and no common treatment-and-pricing dataset exists.
Millions of high-intent healthcare searches begin before a patient reaches a provider.
BBCIndependent market signalPeople look for surgery, diagnostics, dentistry, physiotherapy and cosmetic treatment every month. Much of dentistry and cosmetic care is already self-pay; NHS waiting pressure adds people exploring privately funded options. Their first action is increasingly a Google or AI search—exactly where Medeagle’s structured page-level data and FastTrack Treatment meet them.
Intent pathways“Cost”“Near me”“Book now”TreatmentLocation
“Warnings of two-tier service as polling shows numbers paying for care is on the rise, says watchdog”Read the report ↗
Pressure creates buyers
Long NHS waits and rising out-of-pocket spending are turning private treatment from a niche choice into an active alternative.
Care is being shopped
Patients increasingly search by treatment, price, location and speed — but the market was not built to make those choices easy to compare.
The dataset compounds
Medeagle is building the treatment-and-price map while private supply is still fragmented and before a common comparison standard exists.
NHS pathways waiting
Sustained elective-care pressure is changing how people explore access to treatment.
Source / NHS England ↗Private admissions
UK private hospital admissions reached a fourth consecutive annual record in 2025.
Source / PHIN ↗Hospital revenue from self-pay
Self-pay means the patient pays a private provider directly rather than using medical insurance; it accounted for 28% of private hospital revenue in 2022, including overseas patients.
Source / LaingBuisson / Guardian ↗Used private healthcare
YouGov found 15% used private care for themselves or someone in their immediate household during the previous year.
Source / YouGov ↗EvidenceBuilt / live / backed
Evidence before forecast
This is already in motion.
The forecast starts from a working marketplace, a connected data foundation and institutional support—not a blank proposition.
Next proof layer / verified provider coverage · pricing records · marketplace enquiries
Use of funds12–18 month execution window
The next chapter
Capital turns the foundation into a repeatable engine.
£250kCurrent raise
£250k raised to date£150k deployed
Coverage
Expand and verify the provider and treatment universe.
Automation
Increase extraction, pricing and availability intelligence.
Distribution
Automate provider prospecting and adoption using the core data model.
Milestone-led deployment—not a detailed public budget.Outcome / measurable marketplace engine →
TeamRight to execute
The people behind the graph
Operator-led.
Clinically directed.
Lee leads marketplace product, technology and commercial execution. Thomas leads treatment discovery, clinical pathways and medical relevance. Senior marketplace advisors and practising clinicians extend the team.
Founder, investor & product lead
Lee Manning
Marketplace, online advertising, SEO and shopping-technology operator with hands-on experience shaping and delivering software products for global marketplaces, private-equity funds and high-profile UK brands.
Owns a marketplace advertising business and SEO software company; leads product architecture, technical delivery, provider strategy, partnerships and capital.
Investor & Director of Clinical Strategy
Dr Thomas Moors
CEO of Shout at Cancer, founder and active clinical-strategy leader shaping Medeagle’s treatment discovery, categorisation, patient pathways and medical relevance.
Leads Treatment Discovery & Clinical Pathway Investments—helping organise treatments, symptoms and care-search behaviour into responsible, navigable healthcare intelligence.Senior marketplace advisorsScale, transactions and marketplace transformation
Key advisor & long-term mentor
Phill Jones
Former Andersen / Deloitte advisor specialising in marketplaces, media and transactions; manages £50m+ P&Ls.
Sold Motors.co.uk to eBay for £74m in 2014 and brings marketplace scale-up and deal experience.
CEO, AutoTrader South Africa
George Mienie
AutoTrader SA leader and former OLX / Prosus / Naspers executive who built South Africa’s leading automotive marketplace.
Print to digital to data and AI—direct operating experience in marketplace transformation and automotive intelligence.Growth + capitalCommercial and scaling support
Rita BoothInternational growth specialistInnovate UK government accelerator programme.
Daniel CreighSoftware investorExperience across Zoom and scale-up environments.
Clinical advisoryPractising clinicians and owners
Dr Rajeev AdvaniNHS surgeonPractice owner with a high-profile network.
Dr Moeez Ud-DinNHS & private surgeonPractice owner with a high-profile network.
Sanjeev SilvaConsultant NHS surgeon & directorClinical leadership and pathway insight.
John de CarpentierPrivate surgeonExperienced practice owner.
Dr Raghu ReddyPrivate surgeonOwner of Restore Hair Clinics, Harley Street, London.
04 / Fulfilment layer Staged upside / not in the base case
Discovery reveals the opportunity. Fulfilment captures more of it.
The graph shows where demand, constrained access and attractive economics meet. Start with partners; deepen participation only where the evidence is clear.
01Prove demandIdentify persistent patient intent.→
02Route to partnersMove bookings to trusted capacity.→
03Learn economicsObserve price, conversion and outcomes.→
04Fulfil selectivelyOwn only proven pathways.
Route the booking
The provider delivers care; FastTrack participates through transaction or commission economics.
Own the proven pathway
Launch, operate or acquire capacity only where demand and unit economics have been evidenced.
PathwaysSame-day GPOnline GPADHD diagnosisSexual-health home testing
↺ Fulfilment outcomes, pricing and conversion strengthen the graph.
The base case stands before fulfilment.
The provider marketplace and data/software layer form the modelled core. Partnered and owned fulfilment remain staged upside until live pathways validate their economics. Beyond that, the same infrastructure can support carefully selected adjacent-market and consolidation opportunities.
Modelled
core
core
Provider marketplaceSubscription and platform revenue
Modelled
core
core
Data + softwareReusable intelligence products
Staged
upside
upside
Partner fulfilmentTransaction and commission revenue across verified care pathways.
Patient intent→Referral / health check→Partner care
Staged
upside
upside
Selective ownershipStarting with referral letters and health checks for the over-50s.
10× morepartner / revenue opportunities than a single patient enquiry.
Fulfilment and future-expansion revenue remain outside the published base case pending funded unit-economics and market-entry validation.
( 07 )Illustrative commercial model
Significant outcome / modest captureBase CPC · Base sales · Base costs
The commercial trajectory
The model scales before
the market saturates.
From a management-estimated UK addressable base of approximately 90,000 provider customers, the five-year case requires 3,000+ paying accounts—less than 4% penetration. Sales are led by recurring provider subscriptions, then data and software products.
Forecast scenario controls
Exactly mirrors the management forecast. Revenue and MRR targets stay fixed; sales productivity changes CAC and late-year profit, while costs change the first 36 months of COGS and OPEX.
Sales productivity Management case · CAC
Costs · first 36 months Management case · COGS + OPEX
Modelled CAC£814Y5 operating profit · post-COGS£13.27mY5 EBITDA · forecast definition£13.63m
£15m+Modelled annual revenue
by year five
by year five
£11.34m provider subscriptions+£4.07m data + software=£15.41m total revenue
Y1 · Build£10,877EBITDA -£238,558£100 MRRY2 · Prove£119,800EBITDA -£224,638Y3 · Validate£330,000EBITDA -£77,412£125 MRRY4 · Positive£4,454,000EBITDA £3,681,998Y5 · Scale£15,409,000EBITDA £13,625,228£450 MRR
Forecast P&L snapshotBase sales / Base costs
Base CPC is fixed. All values are copied from the live management forecast at whole-pound display precision.
| Profitability | Y1 | Y2 | Y3 | Y4 | Y5 |
|---|---|---|---|---|---|
| Total revenue | £10,877 | £119,800 | £330,000 | £4,454,000 | £15,409,000 |
| Gross profit | £1,877 | £80,247 | £276,413 | £4,219,246 | £15,051,288 |
| Gross margin | 17% | 67% | 84% | 95% | 98% |
| Operating expenses | £249,435 | £344,438 | £407,412 | £772,002 | £1,783,772 |
| Operating profit (post COGS) | -£247,558 | -£264,191 | -£131,000 | £3,447,244 | £13,267,516 |
| Operating margin | -2276% | -221% | -40% | 77% | 86% |
| EBITDA (forecast definition) | -£238,558 | -£224,638 | -£77,412 | £3,681,998 | £13,625,228 |
Definition note: the forecast workbook labels revenue less operating expenses as “EBITDA”, before COGS. Operating profit above is the post-COGS measure. Source: Medeagle management forecast, updated 29 August 2026; full model available on request.
Recurring monthly fees for claimed profiles, enhanced visibility, qualified patient demand and commercial tools.
Licensing, intelligence products and data feeds built from treatment, pricing and search-demand information.
Transaction and commission revenue from routing proven demand to trusted provider capacity.
Operate or acquire treatment pathways only after demand and unit economics have been evidenced.
3,000+Paying provider accounts
c.90,000Addressable UK providers · <4% required
Y4EBITDA positive
High-90sModelled gross margin
Pricing architecture + sensitivityInternal targets / external context
The revenue benchmark
A measured target.
Visible headroom.
The base case moves deliberately from £100 to £450 monthly recurring revenue per paying provider. The £900 case is a sensitivity—not the plan—and the £1,500 software ceiling is excluded from the five-year base scenario.
Provider subscription revenue
At £450 MRR on the modelled Y5 average paying-account basis.
Provider ARR
At £900 MRR using the same Y5 average paying-account basis.
External context
Different sectors and revenue definitions; shown to frame monetisation range, not as like-for-like forecasts.
Auto Trader
£2,995ARPR / retailer / month · FY2026£1,384 in FY2016 to £2,995 in FY2026—approximately 8% annualised growth.
Rightmove
£1,621Core ARPA / customer / month · 2025Product-led monetisation across agency and new-home customers.
Scout24
€1,224Professional ARPU / month · H1 2026Membership upgrades, value-based pricing and software features.
Mindbody
£89Starting price / location / monthEntry pricing for booking, payments, reporting and discovery software.
Zocdoc
$30–$140Per new-patient bookingPerformance-based monetisation rather than a directly comparable subscription.
Cars.com
$2,500ARPD / dealer / month · Q2 2026A mature marketplace reference for subscription and solutions monetisation.
Additional historic scale references. Doctify: £5.9m reported 2021 revenuethird-party estimate ↗; Treatwell Limited: £56.3m 2022 turnover and £77.5m 2024 turnoverCompanies House filings ↗.
Directional context only. Metrics, currencies, sectors, customer types and revenue definitions are not directly comparable. The Doctify figure is a third-party estimate, not an audited disclosure. Internal targets and sensitivities are illustrative management assumptions.
Illustrative management model—subject to validation and diligence refinement. The approximately 90,000-provider addressable base and headline ranges are management estimates; underlying assumptions are available on request. The 3,000+ account target and revenue sensitivities should be read with the detailed model, which uses average paying-account assumptions by year. Partnered and owned fulfilment revenue is excluded pending funded unit-economics validation.
Investor eligibility · legal notice
Important information.
Please read before acting.
This website has been prepared by Medeagle Limited and has not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. It is directed only at investment professionals within Article 19, high-net-worth entities within Article 49, certified high-net-worth individuals within Article 48, certified or self-certified sophisticated investors within Articles 50 and 50A of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and any other person to whom it may lawfully be communicated (together, “Relevant Persons”). Anyone who is not a Relevant Person must not act on or rely on this website or submit investor interest.
Nothing here is an offer, invitation, recommendation, investment advice or prospectus, and no investment decision should be made from this website alone. Any investment may proceed only through definitive legal documents, investor eligibility checks and due diligence.
Early-stage company shares are high risk and illiquid. Investors may lose all capital invested. Returns, exit timing, valuation and any tax treatment—including SEIS or EIS availability—are not guaranteed. Investors should not expect FSCS protection.
Market sizes, forecasts, targets, valuations, timelines and other forward-looking statements are illustrative management estimates. Actual results may differ materially. Information is incomplete, may change without notice and has not been independently verified.
No representation or warranty is given as to accuracy or completeness, except that liability for fraud is not excluded. Prospective investors should take their own legal, tax and financial advice. Non-public materials supplied after qualification may be confidential on the terms stated when supplied. Information on this page is presented as at 11 August 2026.